**All Interactions with Fosamprenavir (Lexiva)**

| **Coadministered Drug** | **Dose of Drug** | **Dose of Fosamprenavir** | **Effect on Drug Levels** | **Effect on Fosamprenavir Levels** | **Potential Clinical Effects** | **Mechanism of Interaction** | **Management** |
| --- | --- | --- | --- | --- | --- | --- | --- |
| Antacids[130](http://arv.ucsf.edu/insite?page=ar-00-02&param=24&post=4#130),[241](http://arv.ucsf.edu/insite?page=ar-00-02&param=24&post=4#241)  (Maalox, Mylanta, Riopan, Milk of Magnesia, others) | 30 mL x 1 dose | 1400 mg x 1 dose | Not studied | Amprenavir Cmax: decreased 35%; AUC: decreased 18%; Cmin: no significant change | - | - | Dose adjustment not established; may consider separating antacid 2 hours away from fosamprenavir |
| Atazanavir[163](http://arv.ucsf.edu/insite?page=ar-00-02&param=24&post=4#163)  (ATV)(Reyataz) | 200 mg QD x 14 days | 1400 mg QD x 14 days | Atazanavir AUC: decreased 33%; Cmax: decreased 30%; Cmin: decreased 57% | Fosamprenavir AUC: increased 78%; Cmax: increased 36%; Cmin: increased 283% | Increased amprenavir levels | Inhibition of CYP450 3A4 by atazanavir | Dose adjustment not established |
| Atazanavir[159](http://arv.ucsf.edu/insite?page=ar-00-02&param=24&post=4#159)  (ATV)(Reyataz) | 300 mg with 100 mg ritonavir QD on days 1-10, in crossover 300 mg QD when combined with FPV/r 700 mg/100 mg BID | 700 mg BID with 100 mg ritonavir BID on days 1-10 | Atazanavir AUC: decreased 22%; Cmax: decreased 24%; Cmin: no significant change | Amprenavir AUC: no significant change; Cmax: no significant change; Cmin: no significant changeRitonavir AUC: increased 93%; Cmax: increased 96%; Cmin: increased 37% (when ATV 300 mg QD added to FPV/r 700 mg/100 mg BID) | Possibly increased ritonavir effects | Inhibition of CYP450 3A4 by atazanavir and fosamprenavir | No dose adjustment necessary |
| Atazanavir[431](http://arv.ucsf.edu/insite?page=ar-00-02&param=24&post=4#431)  (ATV)(Reyataz) | 400 mg QD | 1400 mg QD | Atazanavir AUC: decreased 33%; Cmax: decreased 27%; Cmin: decreased 60% | Amprenavir AUC: increased 97%; Cmax: increased 58%; Cmin: increased 297% | Increased amprenavir effects; reduced atazanavir effects | Possible induction of CYP450 3A4 by fosamprenavir | Do not coadminister |
| Atorvastatin[218](http://arv.ucsf.edu/insite?page=ar-00-02&param=24&post=4#218) | 10 mg QD | 1400 mg BID or 700 mg fosamprenavir with 100 mg ritonavir BID x 14 days | Atorvastatin AUC: increased 130% (on 1400 mg BID); Cmax: increased 304% (on 1400 mg BID); AUC: increased 153% (on 700/100 mg BID); Cmax: increased 184% (on 700/100 mg BID | Amprenavir AUC: decreased 27% (on 1400 mg BID); Cmax: decreased 18% (on 1400 mg BID) | Increased atorvastatin effects | Inhibition of CYP450 3A4 by amprenavir | Avoid combination if possible; may consider low dose atorvastatin or alternative agents; monitor for myopathy |
| **Coadministered Drug** | **Dose of Drug** | **Dose of Fosamprenavir** | **Effect on Drug Levels** | **Effect on Fosamprenavir Levels** | **Potential Clinical Effects** | **Mechanism of Interaction** | **Management** |
| Atorvastatin[130](http://arv.ucsf.edu/insite?page=ar-00-02&param=24&post=4#130) | 10 mg QD x 4 days | 700 mg BID with ritonavir 100 mg BID x 2 weeks | Atorvastatin Cmax: increased 184%; AUC: increased 153%; Cmin: increased 73% | No significant change | Increased atorvastatin effects (eg, myopathy, rhabdomyolysis) | Inhibition of CYP450 3A4 by fosamprenavir | Avoid combination if possible; may consider low dose atorvastatin or alternative agents; monitor for myopathy  *Alternative Agents*:  **Pravastatin** |
| Atorvastatin[130](http://arv.ucsf.edu/insite?page=ar-00-02&param=24&post=4#130) | 10 mg QD x 4 days | 1400 mg BID x 2 weeks | Atorvastatin Cmax: increased 304%; AUC: increased 130%; Cmin: no significant change | Amprenavir Cmax: decreased 18%; AUC: decreased 27%; Cmin: no significant change | Increased atorvastatin effects (eg, myopathy, rhabdomyolysis) | Inhibition of CYP450 3A4 by fosamprenavir | Avoid combination if possible; may consider low dose atorvastatin or alternative agents; monitor for myopathy |
| Bosentan[727](http://arv.ucsf.edu/insite?page=ar-00-02&param=24&post=4#727) | - | - | - | - | Possible increased bosentan effects | - | Start low and titrate bosentan to effect. If patient has been on protease inhibitor (other than unboosted atazanavir) for more than 10 days, start bosentan at 62.5 mg daily or every other day. If patient is currently on bosentan and requires a PI (other than unboosted atazanavir), stop bosentan for at least 36 hours prior to initiating ART. Wait 10 days and then resume bosentan starting with 62.5 mg daily or every other day. |
| Colchicine[549](http://arv.ucsf.edu/insite?page=ar-00-02&param=24&post=4#549)  (Colcrys) | - | - | - | - | Increased colchicine effects | Inhibition of P450 3A4 by fosamprenavir/ritonavir | For treatment of gout, reduce colchicine dosage to 0.6 mg x 1 then 0.3 mg one hour later. Dose not to be repeated no earlier than 3 days. For prophylaxis of gout, reduce colchicine dosage to 0.3 mg QD if on 0.6 mg BID prior to PI therapy or reduce colchicine dose to 0.3 mg QOD if on 0.6 mg QD prior to PI therapy. For treatment of familial Mediterranean fever: Do not exceed colchicine 0.6 mg once daily or 0.3 mg BID. Do not coadminister in patients with hepatic or renal impairment. |
| Daclatasvir[747](http://arv.ucsf.edu/insite?page=ar-00-02&param=24&post=4#747)  (Daklinza) | - | - | - | - | - | - | No dose adjustment necessary with ritonavir boosted or unboosted fosamprenavir |
| Dasabuvir, Ombitasvir/Paritaprevir/Ritonavir[727](http://arv.ucsf.edu/insite?page=ar-00-02&param=24&post=4#727)  (Viekira) | - | - | - | - | - | - | Do not coadminister |
| **Coadministered Drug** | **Dose of Drug** | **Dose of Fosamprenavir** | **Effect on Drug Levels** | **Effect on Fosamprenavir Levels** | **Potential Clinical Effects** | **Mechanism of Interaction** | **Management** |
| Dolutegravir[641](http://arv.ucsf.edu/insite?page=ar-00-02&param=24&post=4#641)  (Tivicay) | 50 mg QD | 700 mg BID with ritonavir 100 mg BID | Dolutegravir AUC: decreased 35%; Cmin: decreased 49% | - | Potentially reduced dolutegravir effectiveness | - | If no INSTI resistance, increase dolutegravir dosage to 50 mg BID. If known or clinically suspected INSTI resistance, use alternative combination |
| Efavirenz[128](http://arv.ucsf.edu/insite?page=ar-00-02&param=24&post=4#128)  (EFV)(Sustiva) | 600 mg QD x 14 days | 700 mg BID with ritonavir 100 mg BID x 28 days | Not studied | No significant change | - | - | No dose adjustment necessary |
| Efavirenz[128](http://arv.ucsf.edu/insite?page=ar-00-02&param=24&post=4#128)  (EFV)(Sustiva) | 600 mg QD x 14 days | 700 mg BID with ritonavir 200 mg BID x 28 days | Not studied | No significant change | - | - | No dose adjustment necessary |
| Efavirenz[130](http://arv.ucsf.edu/insite?page=ar-00-02&param=24&post=4#130),[131](http://arv.ucsf.edu/insite?page=ar-00-02&param=24&post=4#131)  (EFV)(Sustiva) | 600 mg QD x 2 weeks | 700 mg BID with ritonavir 100 mg BID x 2 weeks | Not studied | No significant change | - | - | No dose adjustment necessary |
| Efavirenz[130](http://arv.ucsf.edu/insite?page=ar-00-02&param=24&post=4#130),[131](http://arv.ucsf.edu/insite?page=ar-00-02&param=24&post=4#131),[129](http://arv.ucsf.edu/insite?page=ar-00-02&param=24&post=4#129)  (EFV)(Sustiva) | 600 mg QD x 2 weeks | 1400 mg QD with ritonavir 200 mg QD x 2 weeks | Not studied | Amprenavir Cmin: decreased 36%; Ritonavir AUC: decreased 31%; Cmin: decreased 40% | Decreased amprenavir effects | Induction of CYP450 3A4 by efavirenz | Increase ritonavir dose to 300 mg when administered with fosamprenavir and efavirenz once daily |
| Efavirenz[131](http://arv.ucsf.edu/insite?page=ar-00-02&param=24&post=4#131)  (EFV)(Sustiva) | 600 mg QD x 2 weeks | 1400 mg QD with 300 mg ritonavir x 2 weeks | Not studied | No significant change | - | Inhibition of CYP450 3A4 by ritonavir compensating for CYP450 3A4 induction by efavirenz | No dose adjustment necessary |
| **Coadministered Drug** | **Dose of Drug** | **Dose of Fosamprenavir** | **Effect on Drug Levels** | **Effect on Fosamprenavir Levels** | **Potential Clinical Effects** | **Mechanism of Interaction** | **Management** |
| Elbasvir/grazoprevir[727](http://arv.ucsf.edu/insite?page=ar-00-02&param=24&post=4#727)  (Zepatier) | - | - | - | - | Potentially increased grazoprevir levels | OATP1B1/3 inhibition by fosamprenavir | Risks likely to outweigh benefits. Consider using alternative agents |
| Elvitegravir/cobicistat[653](http://arv.ucsf.edu/insite?page=ar-00-02&param=24&post=4#653),[639](http://arv.ucsf.edu/insite?page=ar-00-02&param=24&post=4#639)  (Stribild) | Elvitegravir 125 mg QD | 700 mg BID with ritonavir 100 mg BID | No significant change | No significant change | Potentially decreased or increased elvitegravir, cobicistat and/or fosamprenavir effects | - | Do not coadminister |
| Esomeprazole[389](http://arv.ucsf.edu/insite?page=ar-00-02&param=24&post=4#389)  (Nexium) | 20 mg QD x 21 days | 700 mg BID with 100 mg ritonavir BID x 14 days | No significant change | No significant change | - | - | No dose adjustment necessary |
| Esomeprazole[389](http://arv.ucsf.edu/insite?page=ar-00-02&param=24&post=4#389)  (Nexium) | 20 mg QD x 21 days | 1400 mg BID x 14 days | Esomeprazole AUC: increased 55%; Cmax: no significant change | No significant change | - | - | No dose adjustment necessary |
| Etravirine[405](http://arv.ucsf.edu/insite?page=ar-00-02&param=24&post=4#405)  (ETR)(Intelence) | - | 700 mg BID with 100 mg ritonavir BID | - | Fosamprenavir AUC: increased 69%; Cmax: increased 62%; Cmin: increased 77% | Increased fosamprenavir effects | Inhibition of CYP450 by etravirine | Do not coadminister |
| Lopinavir/ritonavir[133](http://arv.ucsf.edu/insite?page=ar-00-02&param=24&post=4#133)  (LPV/r)(Kaletra) | 400/100 mg BID | 700 mg BID with 100 mg ritonavir BID x 2-4 weeks | Lopinavir AUC: decreased 48%; Cmin: decreased 61% | Amprenavir AUC: decreased 64%; Cmin: decreased 69% | Decreased lopinavir and amprenavir effects | Induction of CYP450 3A4 by lopinavir and amprenavir | Do not coadminister |
| **Coadministered Drug** | **Dose of Drug** | **Dose of Fosamprenavir** | **Effect on Drug Levels** | **Effect on Fosamprenavir Levels** | **Potential Clinical Effects** | **Mechanism of Interaction** | **Management** |
| Lopinavir/ritonavir[139](http://arv.ucsf.edu/insite?page=ar-00-02&param=24&post=4#139)  (LPV/r)(Kaletra) | 400/100 mg BID x 10 days | 700 mg BID x 10 days taken simultaneously, 4 hours or 12 hours away from lopinavir/ritonavir dose | Lopinavir AUC (12 hours apart and compared to simultaneous dosing): increased 187%; Cmax: increased 53%; Cmin: increased 69%;Amprenavir AUC: increased 53%; Cmax: increased 56%; Cmin: decreased 71% | Not studied | Decreased amprenavir and increased lopinavir effects | Induction of CYP450 3A4 by lopinavir and amprenavir | Avoid coadministration; Despite separating doses by 12 hours, significant induction still exists when amprenavir and lopinavir levels are compared to historical controls |
| Lopinavir/ritonavir[140](http://arv.ucsf.edu/insite?page=ar-00-02&param=24&post=4#140),[130](http://arv.ucsf.edu/insite?page=ar-00-02&param=24&post=4#130)  (LPV/r)(Kaletra) | 400/100 mg BID x 14 days | 700 mg BID with ritonavir 100 mg BID x 14 days | Lopinavir AUC: increased 37%; Cmax: increased 30%; Cmin: increased 52% | Amprenavir AUC: decreased 63%; Cmax: decreased 58%; Cmin: decreased 65% | Decreased amprenavir effects; increased lopinavir effects | Induction of CYP450 3A4 by lopinavir/ritonavir and inhibition of CYP450 3A4 by amprenavir/ritonavir | Avoid coadministration |
| Lopinavir/ritonavir[140](http://arv.ucsf.edu/insite?page=ar-00-02&param=24&post=4#140),[130](http://arv.ucsf.edu/insite?page=ar-00-02&param=24&post=4#130)  (LPV/r)(Kaletra) | 533/133 mg BID x 14 days | 1400 mg BID x 14 days | No significant change | Amprenavir AUC: decreased 26%; Cmax: no significant change; Cmin: decreased 42% | Decreased amprenavir effects | Induction of CYP450 3A4 by lopinavir/ritonavir | Avoid coadministration |
| Maraviroc[657](http://arv.ucsf.edu/insite?page=ar-00-02&param=24&post=4#657)  (MVC)(Selzentry) | 300 mg BID | 700 mg BID with ritonavir 100 mg BID | Maraviroc AUC: increased 2.49 fold; Cmax: increased 1.52 fold; Cmin: increased 4.75 fold | Amprenavir AUC: decreased 35%; Cmax: decreased 34%; Cmin: decreased 36% Ritonavir AUC: decreased 34%; Cmax: decreased 39%; Cmin: decreased 14% | - | - | Dose adjustment not established. |
| Maraviroc[657](http://arv.ucsf.edu/insite?page=ar-00-02&param=24&post=4#657)  (MVC)(Selzentry) | 300 mg QD | 1400 mg QD with ritonavir 100 mg QD | Maraviroc AUC: increased 2.26 fold; Cmax: increased 1.45 fold; Cmin: increased 1.80 fold | Amprenavir AUC: decreased 30%; Cmax: decreased 29%; Cmin: decreased 15%; Ritonavir AUC: decreased 30%; Cmax: decreased 39%; Cmin: increased 2.66 fold | - | - | Dose adjustment not established |
| Methadone[403](http://arv.ucsf.edu/insite?page=ar-00-02&param=24&post=4#403)  (Dolophine)(Dolophine) | 70-120 mg QD | 700 mg BID with 100 mg ritonavir BID x 14 days | R-methadone AUC: decreased 18%; Cmax: decreased 21% S-methadone AUC: decreased 43%; Cmax: decreased 43%; Cmin: decreased 41% | No significant change | - | Possible displacement of methadone of plasma binding proteins | No dose adjustment necessary |
| **Coadministered Drug** | **Dose of Drug** | **Dose of Fosamprenavir** | **Effect on Drug Levels** | **Effect on Fosamprenavir Levels** | **Potential Clinical Effects** | **Mechanism of Interaction** | **Management** |
| Nevirapine[146](http://arv.ucsf.edu/insite?page=ar-00-02&param=24&post=4#146)  (NVP)(Viramune) | 200 mg BID | 700 mg fosamprenavir BID with 100 mg ritonavir BID | Nevirapine Cmin: increased 22% | No significant change | - | Induction of CYP450 3A4 by nevirapine; inhibition of CYP450 3A4 by ritonavir | No dose adjustment necessary |
| Nevirapine[146](http://arv.ucsf.edu/insite?page=ar-00-02&param=24&post=4#146)  (NVP)(Viramune) | 200 mg BID | 1400 mg BID | Nevirapine AUC: increased 29%; Cmax: increased 25%; Cmin: increased 34% | Fosamprenavir AUC: decreased 33%; Cmax: decreased 25%; Cmin: decreased 35% | Decreased fosamprenavir effects | Induction of CYP450 3A4 by nevirapine | Do not coadminister  *Alternative Agents*:  **Consider ritonavir-boosted fosamprenavir** |
| Paroxetine[394](http://arv.ucsf.edu/insite?page=ar-00-02&param=24&post=4#394)  (Paxil)(Paxil) | 20 mg QD x 10 days | 700 mg BID with 100 mg ritonavir BID | Paroxetine AUC: decreased 55%; Cmax: decreased 60% | Amprenavir: no significant change; Ritonavir: no significant change | Decreased paroxetine effects | - | Titrate paroxetine to effect |
| Phenobarbital[727](http://arv.ucsf.edu/insite?page=ar-00-02&param=24&post=4#727)  (others)(Luminal) | - | - | - | Not studied, may decrease fosamprenavir levels | Potential loss of antiviral efficacy | - | Avoid combination if possible; Do not use with unboosted fosamprenavir or once daily boosted fosamprenavir. Consider alternative agents. If using, monitor and adjust phenobarbital levels as indicated.  *Alternative Agents*:  **Gabapentin Lamotrigine Tiagabine Topiramate** |
| Phenytoin[727](http://arv.ucsf.edu/insite?page=ar-00-02&param=24&post=4#727)  (Dilantin) | - | - | - | Not studied; may decrease fosamprenavir levels. | Potentially decreased antiviral effects. | - | Avoid combination if possible; do not coadminister with unboosted fosamprenavir or once daily boosted fosamprenavir. Consider alternative agents. If using, monitor phenytoin levels and adjust as indicated and monitor for virologic response.  *Alternative Agents*:  **Gabapentin Lamotrigine Tiagabine Topiramate** |
| Posaconazole[447](http://arv.ucsf.edu/insite?page=ar-00-02&param=24&post=4#447)  (Noxafil) | 400 mg BID | 1400 mg BID | Posaconazole AUC: decreased 23%; Cmax: decreased 20% | Amprenavir AUC: decreased 65%; Cmax: decreased 36% (when compared to 700 mg/100 mg fosamprenavir/ritonavir) | Decreased posaconazole and fosamprenavir efficacy | - | Do not coadminister |
| **Coadministered Drug** | **Dose of Drug** | **Dose of Fosamprenavir** | **Effect on Drug Levels** | **Effect on Fosamprenavir Levels** | **Potential Clinical Effects** | **Mechanism of Interaction** | **Management** |
| Raltegravir[440](http://arv.ucsf.edu/insite?page=ar-00-02&param=24&post=4#440)  (RAL)(Isentress) | 400 mg BID | 1400 mg QD with 100 mg ritonavir QD | Raltegravir AUC: decreased 30%; Cmax: decreased 14%; Cmin: decreased 41% | Amprenavir Cmax: increased 27%; Cmin: decreased 17% | - | Possible induction of p-gp | No dose adjustment necessary |
| Raltegravir[440](http://arv.ucsf.edu/insite?page=ar-00-02&param=24&post=4#440)  (RAL)(Isentress) | 400 mg BID | 700 mg fosamprenavir BID with 100 mg ritonavir BID | Raltegravir AUC: decreased 54%; Cmax: decreased 36%; Cmin: decreased 54% | Amprenavir AUC: decreased 25%; Cmin: decreased 33%; Cmax: decreased 25% | - | Possible induction of p-gp | No dose adjustment necessary |
| Raltegravir[440](http://arv.ucsf.edu/insite?page=ar-00-02&param=24&post=4#440)  (RAL)(Isentress) | 400 mg BID | 1400 mg BID | Raltegravir AUC: decreased 29%; Cmin: decreased 68% | Amprenavir AUC: decreased 19%; Cmax: decreased 17%; Cmin: decreased 33% | - | Possible induction of p-gp | No dose adjustment necessary |
| Ranitidine[241](http://arv.ucsf.edu/insite?page=ar-00-02&param=24&post=4#241),[130](http://arv.ucsf.edu/insite?page=ar-00-02&param=24&post=4#130)  (Zantac)(Zantac) | 300 mg x 1 dose | 1400 mg x 1 dose | Not studied | Amprenavir AUC: decreased 30%; Cmax: decreased 51%; Cmin: no significant change | Decreased amprenavir effects | - | Dose adjustment not established |
| Ranolazine[709](http://arv.ucsf.edu/insite?page=ar-00-02&param=24&post=4#709)  (Ranexa) | - | - | Not studied; may increase ranolazine levels | Not studied; may increase fosamprenavir levels | Potential increased ranolazine adverse effects (e.g. prolonged QT, cardiac arrythmias). | - | Do not coadminister |
| Rifabutin[420](http://arv.ucsf.edu/insite?page=ar-00-02&param=24&post=4#420)  (Mycobutin)(Mycobutin) | 150 mg QOD | 700 mg BID with 100 mg ritonavir BID | Rifabutin: no significant change; Desacetylrifabutin AUC: increased 1010%; Cmin: increased 1020%; Cmax: increased 479%; Rifabutin and metabolite AUC: increased 64% (compared to rifabutin 300 mg QD when given alone) | Amprenavir AUC: increased 35%; Cmax: increased 36%;, Cmin: increased 17% (compared to historical controls) | - | Inhibition of CYP450 3A4 by fosamprenavir/ritonavir | No dose adjustment necessary |
| **Coadministered Drug** | **Dose of Drug** | **Dose of Fosamprenavir** | **Effect on Drug Levels** | **Effect on Fosamprenavir Levels** | **Potential Clinical Effects** | **Mechanism of Interaction** | **Management** |
| Ritonavir[129](http://arv.ucsf.edu/insite?page=ar-00-02&param=24&post=4#129)  (RTV)(Norvir) | 300 mg QD | 1400 mg QD with efavirenz 600 mg QD | Not studied | Amprenavir AUC: no significant change; Cmax: increased 18%; Cmin: no significant change | - | Inhibition of CYP450 3A4 by ritonavir | No dose adjustment necessary |
| Rosuvastatin[411](http://arv.ucsf.edu/insite?page=ar-00-02&param=24&post=4#411)  (Crestor) | 10 mg QD | 700 mg BID with ritonavir 100 mg BID | Rosuvastatin Cmax: increased 45% | - | - | - | No dose adjustment necessary |
| Saquinavir[138](http://arv.ucsf.edu/insite?page=ar-00-02&param=24&post=4#138)  (SQV)(Fortovase, Invirase) | 1000 mg BID with ritonavir 100 mg BID on days 1-11 | 700 mg BID on days 2-22 | Saquinavir AUC (with ritonavir 100 mg BID): AUC: no significant change; Cmax: no significant change; Cmin: decreased 24% | Not studied | - | - | No dose adjustment necessary |
| Saquinavir[138](http://arv.ucsf.edu/insite?page=ar-00-02&param=24&post=4#138)  (SQV)(Fortovase, Invirase) | 1000 mg BID with ritonavir 200 mg BID on days 12-22 | 700 mg BID on days 2-22 | Saquinavir AUC (with ritonavir 200 mg BID): no significant change; Cmax: no significant change; Cmin: increased 20% | Not studied | - | - | No dose adjustment necessary |
| Simeprevir[727](http://arv.ucsf.edu/insite?page=ar-00-02&param=24&post=4#727)  (Olysio) | - | - | - | - | - | Inhibition of CYP3A4 potentiating simeprevir effects | Do not coadminister |
| Telaprevir[571](http://arv.ucsf.edu/insite?page=ar-00-02&param=24&post=4#571)  (Incivek) | 1125 mg Q12H x 4 days | 700 mg fosamprenavir with 100 mg ritonavir BID x 24 days | - | Amprenavir AUC: decreased 49%; Cmin: decreased 38%; Cmax: decreased 40% | - | - | Do not coadminister  *Alternative Agents*:  **Atazanavir/ritonavir** |
| Telaprevir[571](http://arv.ucsf.edu/insite?page=ar-00-02&param=24&post=4#571)  (Incivek) | 750 mg Q8H x 10 days | 700 mg fosamprenavir with 100 mg ritonavir BID x 20 days | Telaprevir AUC: decreased 32%; Cmin: decreased 30%; Cmax: decreased 33% | Amprenavir AUC: decreased 47%; Cmin: decreased 56%; Cmax: decreased 35% | Decreased telaprevir effects; decreased amprenavir effects | - | Do not coadminister  *Alternative Agents*:  **Atazanavir/ritonavir** |
| Tenofovir disoproxil fumarate[153](http://arv.ucsf.edu/insite?page=ar-00-02&param=24&post=4#153)  (TDF)(Viread) | 300 mg QD | 1400 mg with 100 mg ritonavir QD x 14 days | No significant change | Amprenavir AUC: no significant change; Cmax: no significant change; Cmin: increased 24% | - | - | No dose adjustment necessary |
| Tenofovir disoproxil fumarate[153](http://arv.ucsf.edu/insite?page=ar-00-02&param=24&post=4#153)  (TDF)(Viread) | 300 mg QD | 1400 mg with 200 mg ritonavir QD x 14 days | No significant change | No significant change | - | - | No dose adjustment necessary |
| "-" indicates that there are no data available | | | | | | | |

|  |  |
| --- | --- |
| 128: | Wire MB, Ballow C, Preston SL, et al. An assessment of plasma amprenavir (APV) pharmacokinetics (PK) following administration of two GW433908 (908) and ritonavir (RTV) regimens in combination with efavirenz (EFV) in healthy adult subjects (APV10010) [abstract #431]. 9th Conference on Retroviruses and Opportunistic Infections; 2002 Feb 24-28; Seattle, Washington. |
| 129: | Wire MB, Preston SL, Ballow C, et al. An assessment of plasma amprenavir pharmacokinetics following administration of two GW433908 and ritonavir QD regimens in combination with efavirenz in healthy adult subjects (APV10009) [abstract #1737]. 41st Interscience Conference on Antimicrobial Agents and Chemotherapy; 2001 September 22-25; Chicago, Illinois. |
| 130: | Lexiva [package insert]. Research Triangle Park, NC: Glaxo Wellcome Inc; Nov 2005. |
| 131: | Wire MB, Ballow C, Preston SL, et al. Pharmacokinetics and safety of GW433908 and ritonavir, with and without efavirenz, in healthy volunteers. AIDS 2004; 18:897-907. |
| 133: | Kashuba ADM, Tierney C, Downey GF, et al. Combining fosamprenavir with lopinavir/ritonavir substantially reduces amprenavir and lopinavir exposure: ACTG protocol A5143 results. AIDS 2005; 19: 145-52. |
| 138: | Boffito M, Dickinson L, Hill A, et al. Steady state pharmacokinetics of saquinavir hard gel/fosamprenavir 1000/700 plus 100 mg and 200 mg of ritonavir twice daily in HIV + patients [abstract #608]. 11th Conference on Retroviruses and Opportunistic Infections; 2004 Feb 8-11; San Francisco, California. |
| 139: | Corbett AH, Davidson L, Park JJ, et al. Dose separation strategies to overcome the pharmacokinetic interaction of a triple protease inhibitor regimen containing fosamprenavir, lopinavir and ritonavir [abstract #611]. 11th Conference on Retroviruses and Opportunistic Infections; 2004 Feb 8-11; San Francisco, California. |
| 140: | Wire MB, Naderer OJ, Masterman AL, et al. The pharmacokinetic interaction between GW433908 and lopinavir/ritonavir (APV10011 and APV10012) [abstract #612]. 11th Conference on Retroviruses and Opportunistic Infections; 2004 Feb 8-11; San Francisco, California. |
| 146: | DeJesus E, Piliero P, Summers K, et al. Evaluation of the pharmacokinetic drug interaction between fosamprenavir, fosamprenavir plus ritonavir and nevirapine in HIV-infected patients [abstract A-447]. 44th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2004 Oct 30-Nov 2; Washington, D.C. |
| 153: | Kurowski M, Walli R, Breske A, et al. Coadministration of tenofovir 300 mg QD with fosamprenavir/ritonavir 1400/100 mg QD or 1400/200 mg QD doses not affect amprenavir pharmacokinetics (COL 20081)[abstact #10]. 6th International Workshop on Clinical Pharmacology of HIV Therapy; 2005 April 28-30; Quebec City, Quebec, Canada. |
| 159: | Wire MB, Shelton MJ, Lou Y, et al. The pharmacokinetic interaction between foramprenavir/ritonavir and atazanavir in healthy adult subjects (APV10018) [poster PE4.3/9]. 10th European AIDS Conference; 2005 November 17-20; Dublin, Ireland. |
| 163: | Clay P, Anderson P, Smith P, et al. Pharmacokinetics of once-daily fosamprenavir 1400 mg plus atazanavir 400 mg without ritonavir in HIV-negative subjects. 13th Conference on Retroviruses and Opportunistic Infections; 2006 Feb 5-8; Denver, Colorado. |
| 218: | Wire MB, Baker KL, Moore KHP, et al. The pharmacokinetic (PK) interaction of GW433908 (908) with atorvastatin (ATO) and 908/ritonavir (RTV) with ATO (APV10013) [abstract #A-1622]. 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy; 2003 September 14-17; Chicago, Illinois. |
| 241: | Ford SL, Wire MB, Lou Y, et al. The effect of antacids and ranitidine on the pharmacokinetics (PK) of GW433908 (908) (APV10007) [abstract #A-1606]. 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy; 2003 September 14-17; Chicago, Illinois. |
| 389: | Shelton MJ, Ford SL, Wire MB, et al. Coadministration of esomeprazole with fosamprenavir has no impact on steady-state plasma amprenavir pharmacokinetics [abstact #24]. 6th International Workshop on Clinical Pharmacology of HIV Therapy; 2005 April 28-30; Quebec City, Quebec, Canada. |
| 394: | van der Lee MJ, Blenke AAM, Rongen GA, et al. Interaction study of the combined use of paroxetine and fosamprenavir-ritonavir in healthy subjects. Antimicrob Ag Chemother 2007; 51: 4098-4104. |
| 403: | Cao Y-J, Smith P, Wire MB, et al. Pharmacokinetics and pharmacodynamics of methadone enantiomers after coadminstration with fosamprenavir-ritonavir in opioid-dependent subjects. Pharmacotherapy 2008; 28: 863-74. |
| 405: | Intelence [package insert]. Raritan, NJ: Tibotec Therapeutics; 2010. |
| 411: | Busti AJ, Bain AM, Hall RG 2nd, et al. Effects of atazanavir/ritonavir or fosamprenavir/ritonavir on the pharmacokinetics of rosuvastatin. J Cardovasc Pharmacol 2008; 51: 605-10. |
| 420: | Ford SL, Chen Y-C, Lou Y, et al. Pharmacokinetic interaction between fosamprenavir-ritonavir and rifabutin in healthy subjects. Antimicrob Ag Chemother 2008; 52: 534-38. |
| 431: | McRay M, Clay PG, Anderson PL, Glaros AG. Pharmacokinetics of concurrent administration of fosamprenavir and atazanavir without ritonavir in human immunodeficiency virus-negative subjects. Pharmacother 2009; 29: 937-42. |
| 440: | Luber A, Slowinski PD, Acosta E, et al. Steady-state pharmacokinetics of fosamprenavir and raltegravir alone and combined with unboosted and ritonavir-boosted fosamprenavir [abstract A1-1297]. 49th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2009 September 12-15; San Francisco, California. |
| 447: | Bruggemann RJM, van Luin M, Colbers EPH, et al. Effect of posaconazole on the pharmacokinetics of fosamprenavir and vice versa in healthy volunteers. J Antimicrob Chemother 2010; 65: 2188-94. |
| 549: | Colcrys [package insert]. Philadelphia, PA: URL Pharma, Inc., May 2010. |
| 571: | Incivek [package insert]. Cambridge, MA: Vertex Pharmaceuticals Inc; May 2011. |
| 639: | DHHS. Guidelines for the use of antiretroviral agents in HIV-1 infected adults and adolescents. Feb 12, 2013. |
| 641: | Tivicay [package insert]. Research Triangle Park, NC: Viiv Healthcare; Sept 2013. |
| 653: | Mathias A, Shen G, Enejosa J, et al. Lack of clinically relevant drug-drug interaction between ritonavir-boosted GS-9137 (elvitegravir) and fosamprenavir/r [abstract WEPEB014]. 4th IAS Conference on HIV Pathogenesis and Treatment and Prevention. Sydney, Australia. |
| 657: | Vourvahis M, Plotka A, Mendes da Costa L, et al. Pharmacokinetic interaction between maraviroc and fosamprenavir/ritonavir: an open lbael, fixed sequence study in healthy volunteers [abstract P 12]. 13th International Workshop on Clinical Pharmacology of HIV Therapy; 2012. Barcelona, Spain. |
| 709: | Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. Available at http://aidsinfo.nih.gov/contentfiles/lvguidelines/AdultandAdolescentGL.pdf. |
| 727: | Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. Available at http://aidsinfo.nih.gov/contentfiles/lvguidelines/AdultandAdolescentGL.pdf. |
| 747: | Daklinza [package insert]. Princeton, NJ: Bristol-Myers Squibb Company, 2016 |